Achille V. C. VC. Manirakiza

Dr. Achille V. C. VC. Manirakiza

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2020 in The Oncologist
Verified
Journal Article
Open access
PDF file
AMAchille V. C. VC. Manirakiza
Achille V. C. VC. Manirakiza
FRFidel Rubagumya
Fidel Rubagumya
LNLouis Ngendahayo
Louis Ngendahayo
Burundi is a landlocked country in the East Central Africa region. Beyond a long civil war strife, cancer care remains overlooked, in terms of both infrastructure and human resources needs, and it shows from estimated global incidence and mortality figures. Through a focused literature search, this study highlights the main cancer care needs in this country, with the aim to gather global oncology support to Burundi. Implications for Practice: There is little knowledge about the state of oncology in Burundi. This article, based on a literature search, depicts an image of the current state of cancer care in Burundi and aims to compel global health enthusiasts to join in curbing the death toll of cancers in Burundi.

24 November 2024 in npj Genomic Medicine
Verified
Journal Article
Open access
PDF file
AMAchille V. C. VC. Manirakiza
Achille V. C. VC. Manirakiza
SBShakuntala Baichoo
Shakuntala Baichoo
AUAnnette UWINEZA
Annette UWINEZA
DDDamas Dukundane
Damas Dukundane
FUFrancois Uwinkindi
Francois Uwinkindi
TRTimothy R. Rebbeck
Timothy R. Rebbeck
Cancer genetic data from Sub-Saharan African (SSA) are limited. Patients with female breast (fBC), male breast (mBC), and prostate cancer (PC) in Rwanda underwent germline genetic testing and counseling. Demographic and disease-specific information was collected. A multi-cancer gene panel was used to identify germline Pathogenic Variants (PV) and Variants of Uncertain Significance (VUS). 400 patients (201 with BC and 199 with PC) were consented and recruited to the study. Data was available for 342 patients: 180 with BC (175 women and 5 men) and 162 men with PC. PV were observed in 18.3% fBC, 4.3% PC, and 20% mBC. BRCA2 was the most common PV. Among non-PV carriers, 65% had ≥1 VUS: 31.8% in PC and 33.6% in BC (female and male). Our findings highlight the need for germline genetic testing and counseling in cancer management in SSA.

28 March 2024 in ecancermedicalscience
Verified
Journal Article
Open access
MBMargaret Baldwin
Margaret Baldwin
BNBrandon A Niyibizi
Brandon A Niyibizi
DRDaniella Rangira
Daniella Rangira
BRBenita Rangira
Benita Rangira
MKMadeleine K Kazindu
Madeleine K Kazindu
AMAchille V. C. VC. Manirakiza
Achille V. C. VC. Manirakiza
Colorectal cancer disease profile and treatment patterns at an urban tertiary hospital in Rwanda Margaret Baldwin1, Brandon A Niyibizi2, Daniella Rangira2,

25 August 2022 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
BNBrandon A. Niyibizi
Brandon A. Niyibizi
EMEulade Muhizi
Eulade Muhizi
DNDiana A. Ndoli
Diana A. Ndoli
IRIvan Rukundo
Ivan Rukundo
TMThierry Z. Muvunyi
Thierry Z. Muvunyi
AMAchille V. C. VC. Manirakiza
Achille V. C. VC. Manirakiza

5 May 2026 in Research Square
Verified
Preprint
Open access
AMAchille V. C. VC. Manirakiza
Achille V. C. VC. Manirakiza
JFJincong J Freeman
Jincong J Freeman
FZFangyuan Zhao
Fangyuan Zhao
EKEmma Keel
Emma Keel
CDChristine Drogan
Christine Drogan
OOOlufunmilayo I. Olopade
Olufunmilayo I. Olopade
Background and Methods: Point of care genetic testing has grown but cascade testing of At-Risk Relatives (ARR) remains underutilized. Between July and September 2023, we surveyed 912 individuals enrolled in the Cancer Prone Study, a registry of diverse high-risk families who received genetic counseling from cancer genetic experts. We analyzed correlates of familial disclosure and cascade testing among carriers of pathogenic/likely pathogenic variants (PV). Data on carrier status of PV in cancer-predisposing genes, penetrance level of variants, receipt of a family letter, familial disclosure, and follow up cascade testing of ARRs were collected. Results: Of 912 respondents, 39.4% were carriers of PV. Among these carriers, 78% had highly penetrant PVs (most common genes were BRCA1 : 39% and BRCA2 : 18%) and 17.5% had moderate penetrance PVs; Rate of disclosure of PV to at least one family member; receipt of family letter explaining genetic test results; and sharing of information with ARRs were 98%, 69% and 82% respectively. Cascade testing was more likely among carriers with highly penetrance PV (91.1%) compared to those with moderate penetrance PV (58.3%) (adjusted odds ratio [AOR], 5.70; 95% CI, 2.03-16.02), and among carriers who received a family letter than among those who did not receive (87.2% vs. 73.0%; AOR, 3.70; 95% CI, 1.42-9.61). These data suggest that access to family-based counseling facilitated by cancer genetic experts improves understanding of familial risks and improves cascade testing following results disclosure. Our data support family based clinical interventions to optimize precision prevention and cancer control in high-risk individuals.

14 May 2026 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
FRFidel Rubagumya
Fidel Rubagumya
SVShankar Viswanathan
Shankar Viswanathan
VKVincent Kwizera
Vincent Kwizera
DNDiane A. Ndoli
Diane A. Ndoli
CUClaire Umubyeyi
Claire Umubyeyi
RKRafi Kabiriti
Rafi Kabiriti